MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.180
-0.340
-9.66%
After Hours: 3.210 +0.03 +0.94% 18:04 05/28 EDT
OPEN
3.530
PREV CLOSE
3.520
HIGH
3.570
LOW
3.140
VOLUME
453.21K
TURNOVER
--
52 WEEK HIGH
4.400
52 WEEK LOW
1.190
MARKET CAP
196.94M
P/E (TTM)
-1.7355
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CMRX stock price target is 8.50 with a high estimate of 10.00 and a low estimate of 7.00.

EPS

CMRX News

More
Chimerix to Present at Jefferies Virtual Healthcare Conference
Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at th
GlobeNewswire · 16h ago
70 Biggest Movers From Friday
Gainers Sorrento Therapeutics, Inc (NASDAQ: SRNE) shares climbed 158% to close at $6.76 on Friday amid investor attention surrounding the company's STI-1499 coronavirus antibody.
Benzinga · 05/18 08:47
75 Biggest Movers From Yesterday
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares climbed 88% to close at $4.14 on Wednesday following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/14 08:26
Chimerix Shares Spike to Highs; CEO Appearing on Fox Business
Benzinga · 05/13 19:23
Revenue Downgrade: Here's What Analysts Forecast For Chimerix, Inc. (NASDAQ:CMRX)
Simply Wall St. · 05/12 11:47
Chimerix EPS misses by $0.02, misses on revenue
Chimerix (NASDAQ:CMRX): Q1 GAAP EPS of -$0.17 misses by $0.02. Revenue of $1.24M (-47.5% Y/Y) misses by $0.51M. Press Release
seekingalpha · 05/07 16:23
Chimerix (CMRX) Reports Q1 Loss, Lags Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/07 14:25
Recap: Chimerix Q1 Earnings
Shares of Chimerix (NASDAQ:CMRX) were unchanged at $2.52 after the company reported Q1 results. Quarterly Results Earnings per share rose 51.43% over the past year to ($0.17), which missed the estimate of ($0.15). Revenue of $1,241,000 lower by 47.33% year ove
Benzinga · 05/07 13:07

Industry

Biotechnology & Medical Research
+0.35%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About CMRX

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
More

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.